G6PD and COVID-19: G6PD deficient individuals are at high risk of severe hemolysis when given anti-malarial drugs such as primaquine, quinine, other sulphonamide-containing medicines [6,7,8], and chloroquine which has been shown to be potent for the treatment of coronavirus disease (COVID-19) [6,9,10], These drugs may cause an irreversible oxidative activity of the body’s metabolites on erythrocytes [7,8].